Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease

Vascular Medicine

Volumn 15, Issue 3, 2010, Pages 171-179

  Hiatt, William R ^a   Hirsch, Alan T ^b   Creager, Mark A ^c   Rajagopalan, Sanjay ^d   Mohler, Emile R ^e   Ballantyne, Christie M ^f   Regensteiner, Judith G ^a   Treat Jacobson, Diane ^g   Dale, Rita A ^h  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h Colorado Prevention Center ^*  (United States)

Author keywords

Atherosclerosis; Cholesterol; Claudication; Clinical trials; Drug therapy; Exercise test; HDL; Hyperlipidemia; LDL; Multicenter studies; Peripheral arterial disease

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID;

ADULT; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; BACKACHE; CHOLESTEROL BLOOD LEVEL; CLAUDICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FLUSHING; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTENSION; INFLUENZA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SAFETY; PERIPHERAL VASCULAR DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; THROMBOCYTE COUNT; TREADMILL EXERCISE;

AGED; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; EXERCISE TEST; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERMITTENT CLAUDICATION; LOVASTATIN; MALE; MIDDLE AGED; NIACIN; PERIPHERAL ARTERIAL DISEASE; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 77952576925     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X09360579     Document Type: Article

References (27)

1. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/ AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006 ; 47: 1239-1312.
2. Norgren L., Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007 ; 45: S5 - S67.
3. Regensteiner JG, Ware JE Jr, McCarthy WJ, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002 ; 50: 1939-1946.
4. Hiatt WR, Money SR, Brass EP Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg 2008 ; 47: 330-336.
5. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007 ; 45: 645-654.
6. Mohler ER III, Hiatt WR, Creager MA Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003 ; 108: 1481-1486.
7. Mondillo S., Ballo P., Barbati R., et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003 ; 114: 359-364.
8. Aronow WS, Nayak D., Woodworth S., Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003 ; 92: 711-712.
9. Brown BG, Zhao XQ, Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001 ; 345: 1583-1592.
10. Thoenes M., Oguchi A., Nagamia S., et al. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int J Clin Pract 2007 ; 61: 1942-1948.
11. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004 ; 110: 3512-3517.
12. Blankenhorn DH, Azen SP, Crawford DW, et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation 1991 ; 83: 438-447.
13. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 ; 285: 2486-2497.
14. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975 ; 231: 360-381.
15. Phillips PS, Phillips CT, Sullivan MJ, Naviaux RK, Haas RH Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis 2004 ; 177: 183-188.
16. Paolisso G., Barbagallo M., Petrella G., et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 2000 ; 150: 121-127.
17. Blanco-Colio LM, Martin-Ventura JL, de Teresa E., et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J 2007 ; 153: 881-888.
18. Brunetti ND, Maulucci G., Casavecchia GP, et al. Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg. J Interv Cardiol 2007 ; 20: 481-487.
19. Beckman JA, Liao JK, Hurley S., et al. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res 2004 ; 95: 217-223.
20. Brown BG, Zhao XQ Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 2008 ; 101: 58B - 62B.
21. Kamanna VS, Kashyap ML Mechanism of action of niacin. Am J Cardiol 2008 ; 101: 20B - 26B.
22. Ganji SH, Qin S., Zhang L., Kamanna VS, Kashyap ML Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009 ; 202: 68-75.
23. Warnholtz A., Wild P., Ostad MA, et al. Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. Atherosclerosis 2009 ; 204: 216-221.
24. Zhao XQ, Yuan C., Hatsukami TS, et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 2001 ; 21: 1623-1629.
25. Phan BA, Chu B., Polissar N., Hatsukami TS, Yuan C., Zhao XQ Association of high-density lipoprotein levels and carotid atherosclerotic plaque characteristics by magnetic resonance imaging. Int J Cardiovasc Imaging 2007 ; 23: 337-342. (Pubitemid 46767508)
26. Vittone F., Chait A., Morse JS, Fish B., Brown BG, Zhao XQ Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: a subgroup analysis of the HDL-Atherosclerosis Treatment Study (HATS). J Clin Lipidol 2007 ; 1: 203-210.
27. Goldberg RB, Jacobson TA Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 2008 ; 83: 470-478.